FASN and breast cancer: Interestingly, in the presence of the FASN inhibitor C75, the ERα antagonist ICI 182 780, and the MAPK inhibitor U0126, E2-stimulated ERα-driven transcriptional activity reverts to the basal level seen in E2-depleted breast cancer cells.